Revance announces proposed public offering of common stock
NEWARK, Calif.,--(BUSINESS WIRE)--Dec. 3, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. Revance Therapeutics, Inc. RVNC, -0.45%, a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in which it will issue and sell approximately $175 million of shares of its common stock. In addition, certain stockholders of the Company (the "Selling Stockholders") are offering 600,000 shares of the Company's Revance Announces Pricing of Public Offering of Common Stock shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to RVNC, -1.59% a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock.
Revance Therapeutics, Inc. RVNC, -0.45%, a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”),
Revance Announces Proposed Public Offering of Common Stock. December 03, 2019 04:01 PM Eastern Standard Time. NEWARK, Calif.,--(BUSINESS 10 Feb 2020 The notes will be convertible into cash, shares of Revance's common stock or a combination of cash and shares of Revance's common stock, 19 Feb 2020 To the extent the underwriters exercise their option to purchase additional shares of common stock, the Company intends to use the net proceeds Revance Announces Proposed Private Offering Of $200 Mln Of Convertible Senior BRIEF-Revance Announces Proposed Public Offering Of Common Stock. 6 Feb 2020 miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock. Email Print Friendly Share. February Revance Announces Proposed Public Offering of Common Stock - Dec. 3, 2019. 12/3/2019. Revance Therapeutics, Inc. announced a proposed underwritten 8 Jan 2020 (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common
Revance Announces Pricing of Public Offering of Common Stock shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to
NEWARK, Calif.,--(BUSINESS WIRE)--Dec. 3, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. Revance Therapeutics, Inc. RVNC, -0.45%, a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in which it will issue and sell approximately $175 million of shares of its common stock. In addition, certain stockholders of the Company (the "Selling Stockholders") are offering 600,000 shares of the Company's Revance Announces Pricing of Public Offering of Common Stock shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to RVNC, -1.59% a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock. In addition, certain stockholders of the Company (the “Selling Stockholders”) are offering 600,000 shares of the Company’s common stock for sale to the public. NEWARK, Calif.,--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic
4 Dec 2019 Revance Therapeutics, Inc., a biotechnology company developing next- generation neuromodulators for use in treating aesthetic and
NEWARK, Calif.--(BUSINESS WIRE)--Jan. 22, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the closing of an underwritten public offering of 6,764,705 shares of its common stock at a price to the public of $17.00 per share, including the exercise in full by the underwriters of their option to purchase 882,352 Revance Therapeutics Announces Proposed Public Offering of Common Stock November 02, 2015 NEWARK, Calif. , Nov. 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,250,000 shares of its common stock. Revance Therapeutics, Inc. RVNC, -7.01% today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a registration statement filed with the NEWARK, Calif.,--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock.
In addition, certain stockholders of the Company (the “Selling Stockholders”) are offering 600,000 shares of the Company’s common stock for sale to the public.
19 Feb 2020 To the extent the underwriters exercise their option to purchase additional shares of common stock, the Company intends to use the net proceeds Revance Announces Proposed Private Offering Of $200 Mln Of Convertible Senior BRIEF-Revance Announces Proposed Public Offering Of Common Stock. 6 Feb 2020 miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock. Email Print Friendly Share. February Revance Announces Proposed Public Offering of Common Stock - Dec. 3, 2019. 12/3/2019. Revance Therapeutics, Inc. announced a proposed underwritten 8 Jan 2020 (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common 4 Dec 2019 Revance Therapeutics, Inc., a biotechnology company developing next- generation neuromodulators for use in treating aesthetic and Revance Announces Pricing Of $250 Million Of Convertible Senior Notes Due 2027 Revance Announces Proposed Public Offering Of Common Stock.
Tax Planning; Personal Finance; Save for College; Save for Retirement; Invest in Retirement NEWARK, Calif.,--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic RVNC, +0.29%, a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share. NEWARK, Calif.,--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC) , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research and development and general